A variety of indications are treated by these devices, including opioid use disorder and cannabis cravings, neonatal opioid withdrawal syndrome (NOWS) and nicotine addiction. It is expected that 27 of the 37 clinical trials and 24 in early stages of development will be approved by 2025. This is out of the 37 in clinical trials and 24 in early stages of development.
